Time-Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers

Clinical Therapeutics

Volumn 34, Issue 12, 2012, Pages 2333-2338

  Li, Jiaqi ^a   Wang, Yijun ^a   Han, Lina ^a   Sun, Xiaodong ^a   Yu, Honglin ^a   Yu, Yerong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ISOPHANE INSULIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHINESE; DRUG CAPSULE; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; NORMAL HUMAN; PHARMACODYNAMICS; TIME ACTION;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; CAPSULES; CHINA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, ISOPHANE; TIME FACTORS; YOUNG ADULT;

EID: 84870751256     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.11.004     Document Type: Article

References (24)

1. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26(Suppl 3):S18-S24.
2. Hunt L.M., Valenzuela M.A., Pugh J.A. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997, 20:292-298.
3. Zambanini A., Feher M.D. Needle phobia in type 1 diabetes mellitus. Diabet Med 1997, 14:321-323.
4. Owens D.R., Zinman B., Bolli G. Alternative routes of insulin delivery. Diabet Med 2003, 20:886-898.
5. Berger M. Oral insulin 1922-1992. The history of continuous ambition and failure. Frontiers in Insulin Pharmacology 1993, 144-148. Georg Thieme Verlag, Stuttgart, Germany. M. Berger, F.A. Gries (Eds.).
6. Hamman J.H., Enslin G.M., Kotzé A.F. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005, 19:165-177.
7. Still J.G. Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002, 18(Suppl 1):S29-S37.
8. Brange J., Langkjoer L. Insulin formulation and delivery. Protein Delivery: Physical Systems 1997, 343-411. Plenum Press, New York, NY. L.M. Sanders, R.W. Hendren (Eds.).
9. Amiel S.A., Alberti K.G. Inhaled insulin. BMJ 2004, 328:1215-1216.
10. Xia C.Q., Wang J., Shen W.C. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2000, 295:594-600.
11. Morishita M., Goto T., Peppas N.A., et al. Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption. J Control Rel 2004, 97:115-124.
12. Shao Z., Li Y., Chermak T., Mitra A.K. Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of beta-cyclodextrin derivatives on alpha-chymotryptic degradation and enteral absorption of insulin in rats. Pharm Res 1994, 11:1174-1179.
13. Gwinup G., Elias N., Domurat E.S. Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules. Gen Pharmacol 1991, 22:243-246.
14. Ceflau W.T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004, 27:239-246.
15. Damgé C., Catarina P.R., Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008, 5:45-68.
16. Chiou W.L. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978, 6:539-546.
17. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
18. Korytkowski M. When oral agents fail; practical barriers to starting insulin. Int J Obes 2002, 26(Suppl 3):S18-S24.
19. Skyler J.S. Lessons from studies of insulin pharmacokinetics. Diabetes Care 1986, 9:666-668.
20. Heinemann L., Pfützner A., Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001, 7:1327-1351.
21. Arbit E. The physiological rationale for oral insulin administration. Diab Technol Ther 2004, 6:510-517.
22. Eaton R.P., Allen R.C., Schade D.S. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983, 56:1294-1300.
23. Khedkar A., Iyer H., Anand A., et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab 2010, 12:659-664.
24. Starke A.A., Heinemann L., Hohmann A., Berger M. The action profiles of human NPH insulin preparations. Diabet Med 1989, 6:239-244.